SEARCH

SEARCH BY CITATION

References

  • 1
    Jones R & Lydeard S. Irritable bowel syndrome in the general population. Br Med J 1992; 304: 87 90.
  • 2
    Harvey R, Read A, Salih Y. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983; 1: 632 4.
  • 3
    Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999; 60: 77 81.
  • 4
    Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1019 30.
  • 5
    Farthing M. Irritable bowel, irritable body, irritable brain? Br Med J 1995; 310: 171 5.
  • 6
    Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120 37.
  • 7
    Thompson W, Longstreth G, Drossman D et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. II): 43 7.
  • 8
    Klein K. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232 41.
  • 9
    Pattee PL & Thompson WG. Drug treatment of the irritable bowel syndrome. Drugs 1992; 44: 200 6.
  • 10
    Bardhan K, Bodemar G, GeldofH et al. A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Gastroenterology 1996; 110; A630A630 (Abstract).
  • 11
    Camilleri M, Mayer E, Drossman D et al. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5–HT3-receptor antagonist . Aliment Pharmacol Ther 1999; 13: 1149 59.
  • 12
    Mangel AW, Camilleri M, Chey WY et al. Treatment of female IBS patients with alosetron, a potent and selective 5HT3-receptor antagonist . Gastroenterology 1999; 116: A1036A1036(Abstract).
  • 13
    Gershon M. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13: 15 30.
  • 14
    Delvaux M, Louvel D, Mamet JP et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849 55.
  • 15
    Goldberg PA, Kamm MA, Setti-Carraro P et al. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996; 57: 478 83.
  • 16
    Prior A & Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome . Aliment Pharmacol Ther 1993; 7: 175 80.
  • 17
    Zighelboim J, Talley NJ, Phillips SF et al. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819 27.
  • 18
    Baume P. Mebeverine, an effective agent in the irritable colon syndrome. Aust N Z J Med 1972; 2: 34 6.
  • 19
    Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther 1996; 10: 787 93.
  • 20
    Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J 1965; 5466: 848 51.
  • 21
    Thompson W, Creed F, Drossman D et al. Functional bowel disorders and functional abdominal pain. Gastrointest J 1992; 5: 75 91.
  • 22
    Harding JP, Hamm LR, Ehsanullah RSB et al. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1073 6.
  • 23
    Mantel N & Haenszel W. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 1959; 22: 719 48.
  • 24
    Van Elteren P. On the combination of independent two sample tests of Wilcoxon. Bull Int Stat Inst 1960; 37: 351 61.
  • 25
    Dan Hertog A & Vanden Akker J. Modification of alpha 1-receptor operated channels by mebeverine in smooth muscle cells of guinea-pig taenia caeci. Eur J Pharmacol 1987; 138: 367 74.
  • 26
    Poynard T, Naveau S, Mory B et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499 510.
  • 27
    Le Gal M & Pelouz C. Colopathie fonctionelle. Une étude multicentrique rassemblant 1147 malades a confirmé l’efficacité de Duspatalin′ suspension, sur les symptômes de colopathie, ainsi qu’une bonne tolérance et une excellente acceptabilité. Impact Med 1989; 3: 70 3.
  • 28
    Guyot P. Efficacité de la mébévérine (Duspatalin′ 200 mg gélule) chez des patients présentant des troubles fonctionnels intestinaux: résultats d’une étude descriptive en fonction des différents sous-groupes symptomatiques. Act Méd Int Gastroentérol 1997; 11: 40 5.
  • 29
    Mangel AW, Hahn BA, Heath AT et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998; 26: 76 81.
  • 30
    Mangel AW, Northcutt AR, Kong S et al. Validation of adequate relief as an endpoint in irritable bowel syndrome. Gastroenterology 1999; 116: A1035A1035(Abstract).
  • 31
    Northcutt A, Harding J, Kong S et al. Urgency as an endpoint in IBS. Gastroenterology 1999; 116: A1036A1036(Abstract).
  • 32
    Watson MW, Lacey LA, McSorley D, Northcutt A, Mangel A. Impact of alosetron on health-related quality of life (HRQOL) in female patients with irritable bowel syndrome (IBS). Am J Gastroenteol 1999; 94: 27622762(Abstract 741).